The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Targeting oxidative stress in beta-thalassemia and SCD
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, comments on redox balance in beta-thalassemia and sickle cell disease (SCD), discussing the potential of targeting oxidative stress to treat these conditions. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Member of the advisory board for Celgene and BMS
